Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27454752 | 1.00 | KCNH2 (0.34) | KCNH2PTPN11HRH3CYP2D6PRCP | |
| SCHEMBL27452969 | 0.86 | PTPN11 (0.33) | PTPN11HRH3CYP2D6 | |
| SCHEMBL27452967 | 0.86 | PTPN11 (0.33) | PTPN11HRH3CYP2D6 | |
| SCHEMBL27461083 | 0.86 | KCNH2 (0.35) | KCNH2PTPN11 | |
| SCHEMBL27454742 | 0.78 | KCNH2 (0.49) | KCNH2HRH3CYP2D6DPP4 | |
| SCHEMBL27461065 | 0.78 | KCNH2 (0.49) | KCNH2HRH3CYP2D6DPP4 | |
| SCHEMBL27452968 | 0.78 | PTPN11 (0.47) | KCNH2PTPN11HRH3CYP2D6P2RX7 | |
| SCHEMBL22520411 | 0.78 | PTPN11 (0.47) | KCNH2PTPN11HRH3CYP2D6P2RX7 | |
| SCHEMBL24878774 | 0.75 | KCNH2 (0.41) | KCNH2PTPN11HRH3CYP2D6DPP4 | |
| SCHEMBL24091214 | 0.74 | PTPN11 (0.43) | KCNH2PTPN11HRH3CYP2D6PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | KCNH2 4661/4885PTPN11 16/4885HRH3 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.